Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

John D. Imig PhD

John D. Imig PhD

Professor

Institution: Medical College of Wisconsin
Department: Pharmacology and Toxicology
Program: Program Development

Member of the Cancer Center
Member of the Cardiovascular Center


Publications

  • Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats. (Alánová P, Husková Z, Kopkan L, Sporková A, Jíchová Š, Neckář J, Imig JD, Klevstig M, Kolář F, Rami Reddy N, Falck JR, Sadowski J, Nishiyama A, Kramer HJ, Melenovský V, Červenková L, Kujal P, Vernerová Z, Červenka L) Vascul Pharmacol 2015 Aug 22: PMID: 26304700 08/26/2015
  • Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula. (Červenka L, Melenovský V, Husková Z, Sporková A, Bürgelová M, Škaroupková P, Hwang SH, Hammock BD, Imig JD, Sadowski J) Physiol Res 2015 Jun 5: PMID: 26047375 06/06/2015
  • Tumour necrosis factor-α contributes to improved cardiac ischaemic tolerance in rats adapted to chronic continuous hypoxia. (Chytilová A, Borchert GH, Mandíková-Alánová P, Hlaváčková M, Kopkan L, Khan MA, Imig JD, Kolář F, Neckář J) Acta Physiol (Oxf) 2015 May;214(1):97-108 PMID: 25760892 03/12/2015
  • Epoxyeicosatrienoic acids, hypertension, and kidney injury. (Imig JD) Hypertension 2015 Mar;65(3):476-82 PMID: 25583156 PMCID: PMC4326585 01/15/2015
  • Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. (Kim J, Yoon SP, Toews ML, Imig JD, Hwang SH, Hammock BD, Padanilam BJ) Am J Physiol Renal Physiol 2015 Jan 15;308(2):F131-9 PMID: 25377915 PMCID: PMC4338924 11/08/2014
  • Correction to 14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) Surrogates: Carboxylate Modifications. (Falck JR, Koduru SR, Mohapatra S, Manne R, Atcha KR, Manthati VL, Capdevila JH, Christian S, Imig JD, Campbell WB) J Med Chem 2014 Nov 13;57(21):9218 PMID: 25369142 PMCID: PMC4234425 11/05/2014
  • Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury. (Khan AH, Falck JR, Manthati VL, Campbell WB, Imig JD) Front Pharmacol 2014;5:216 PMID: 25295006 PMCID: PMC4172029 10/09/2014
  • Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. (Sporková A, Jíchová S, Husková Z, Kopkan L, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kompanowska-Jezierska E, Sadowski J, Kramer HJ, Cervenka L) Clin Exp Pharmacol Physiol 2014 Dec;41(12):1003-13 PMID: 25224811 PMCID: PMC4347520 09/17/2014
  • Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation. (Kim J, Imig JD, Yang J, Hammock BD, Padanilam BJ) Am J Physiol Renal Physiol 2014 Oct 15;307(8):F971-80 PMID: 25164080 PMCID: PMC4200297 08/29/2014
  • 14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) surrogates: carboxylate modifications. (Falck JR, Koduru SR, Mohapatra S, Manne R, Atcha R, Manthati VL, Capdevila JH, Christian S, Imig JD, Campbell WB) J Med Chem 2014 Aug 28;57(16):6965-72 PMID: 25119815 PMCID: PMC4148164 08/15/2014
  • Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy. (Gangadhariah MH, Luther JM, Garcia V, Paueksakon P, Zhang MZ, Hayward SW, Love HD, Falck JR, Manthati VL, Imig JD, Schwartzman ML, Zent R, Capdevila JH, Pozzi A) J Am Soc Nephrol 2015 Mar;26(3):597-610 PMID: 25071086 PMCID: PMC4341468 07/30/2014
  • Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. (Hye Khan MA, Neckář J, Cummens B, Wahl GM, Imig JD) Cardiovasc Drugs Ther 2014 Aug;28(4):313-22 PMID: 24842561 05/21/2014
  • Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. (Hye Khan MA, Pavlov TS, Christain SV, Neckář J, Staruschenko A, Gauthier KM, Capdevila JH, Falck JR, Campbell WB, Imig JD) Clin Sci (Lond) 2014 Oct;127(7):463-74 PMID: 24707975 PMCID: PMC4167712 04/09/2014
  • Azilsartan improves glycemic status and reduces kidney damage in zucker diabetic fatty rats. (Hye Khan MA, Neckář J, Haines J, Imig JD) Am J Hypertens 2014 Aug;27(8):1087-95 PMID: 24598210 03/07/2014
  • Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. (Kujal P, Čertíková Chábová V, Škaroupková P, Husková Z, Vernerová Z, Kramer HJ, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kitada K, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Červenka L) Clin Exp Pharmacol Physiol 2014 Mar;41(3):227-37 PMID: 24471737 PMCID: PMC4038339 01/30/2014
  • Fructose stimulates Na/H exchange activity and sensitizes the proximal tubule to angiotensin II. (Cabral PD, Hong NJ, Hye Khan MA, Ortiz PA, Beierwaltes WH, Imig JD, Garvin JL) Hypertension 2014 Mar;63(3):e68-73 PMID: 24379189 01/01/2014
  • The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt. (Capdevila JH, Pidkovka N, Mei S, Gong Y, Falck JR, Imig JD, Harris RC, Wang W) J Biol Chem 2014 Feb 14;289(7):4377-86 PMID: 24368771 PMCID: PMC3924300 12/26/2013
  • Thioredoxin-interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. (Mohamed IN, Hafez SS, Fairaq A, Ergul A, Imig JD, El-Remessy AB) Diabetologia 2014 Feb;57(2):413-23 PMID: 24201577 PMCID: PMC3947289 11/10/2013
  • Afferent Arteriolar Responses to β,γ-methylene ATP and 20-HETE are not Blocked by ENaC Inhibition. (Nagasawa T, Imig JD) Physiol Rep 2013 Sep 1;1(4):e00082 PMID: 24159379 PMCID: PMC3804346 10/26/2013
  • Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat. (Hye Khan MA, Neckár J, Manthati V, Errabelli R, Pavlov TS, Staruschenko A, Falck JR, Imig JD) Hypertension 2013 Nov;62(5):905-13 PMID: 23980070 PMCID: PMC3872985 08/28/2013
  • Immune and inflammatory role in renal disease. (Imig JD, Ryan MJ) Compr Physiol 2013 Apr;3(2):957-76 PMID: 23720336 PMCID: PMC3803162 05/31/2013
  • Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. (Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif AM, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD, Hammock BD) J Cardiovasc Pharmacol 2013 Sep;62(3):285-97 PMID: 23676336 PMCID: PMC3773051 05/17/2013
  • Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. (Khan MA, Liu J, Kumar G, Skapek SX, Falck JR, Imig JD) FASEB J 2013 Aug;27(8):2946-56 PMID: 23603837 PMCID: PMC3714587 04/23/2013
  • Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats. (Imig JD, Walsh KA, Hye Khan MA, Nagasawa T, Cherian-Shaw M, Shaw SM, Hammock BD) Exp Biol Med (Maywood) 2012 Dec;237(12):1402-12 PMID: 23354399 PMCID: PMC3613242 01/29/2013
  • Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. (Imig JD) Prostaglandins Other Lipid Mediat 2013 Jul-Aug;104-105:2-7 PMID: 23333581 PMCID: PMC3664103 01/22/2013
  • Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. (Honetschlägerová Z, Kitada K, Husková Z, Sporková A, Kopkan L, Bürgelová M, Varcabová Š, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerová Z, Červenka L) J Hypertens 2013 Feb;31(2):321-32 PMID: 23307303 PMCID: PMC3773167 01/12/2013
  • Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system. (Varcabova S, Huskova Z, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Kitada K, Cervenka L) Clin Exp Pharmacol Physiol 2013 Apr;40(4):273-81 PMID: 23039246 PMCID: PMC3769696 10/09/2012
  • Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. (Kopkan L, Husková Z, Sporková A, Varcabová Š, Honetschlägerová Z, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Kramer HJ, Bürgelová M, Vojtíšková A, Kujal P, Vernerová Z, Červenka L) Kidney Blood Press Res 2012;35(6):595-607 PMID: 22948718 PMCID: PMC3604982 09/06/2012
  • Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. (Nagasawa T, Hye Khan MA, Imig JD) Clin Exp Pharmacol Physiol 2012 May;39(5):454-61 PMID: 22443474 PMCID: PMC3613249 03/27/2012
  • Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. (Neckář J, Kopkan L, Husková Z, Kolář F, Papoušek F, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Malý J, Netuka I, Ošťádal B, Červenka L) Clin Sci (Lond) 2012 Jun;122(11):513-25 PMID: 22324471 PMCID: PMC3528350 02/14/2012
  • 11,12,20-Trihydroxy-eicosa-8(Z)-enoic acid: a selective inhibitor of 11,12-EET-induced relaxations of bovine coronary and rat mesenteric arteries. (Bukhari IA, Shah AJ, Gauthier KM, Walsh KA, Koduru SR, Imig JD, Falck JR, Campbell WB) Am J Physiol Heart Circ Physiol 2012 Apr 15;302(8):H1574-83 PMID: 22307677 PMCID: PMC3330801 02/07/2012
  • Epoxides and soluble epoxide hydrolase in cardiovascular physiology. (Imig JD) Physiol Rev 2012 Jan;92(1):101-30 PMID: 22298653 PMCID: PMC3613253 02/03/2012
  • Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. (Elmarakby AA, Faulkner J, Al-Shabrawey M, Wang MH, Maddipati KR, Imig JD) Am J Physiol Regul Integr Comp Physiol 2011 Nov;301(5):R1307-17 PMID: 21832210 PMCID: PMC3213948 08/13/2011
  • Glomerular expression of kidney injury molecule-1 and podocytopenia in diabetic glomerulopathy. (Zhao X, Zhang Y, Li L, Mann D, Imig JD, Emmett N, Gibbons G, Jin LM) Am J Nephrol 2011;34(3):268-80 PMID: 21822010 PMCID: PMC3169370 08/09/2011
  • Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles. (Gauthier KM, Olson L, Harder A, Isbell M, Imig JD, Gutterman DD, Falck JR, Campbell WB) Am J Physiol Renal Physiol 2011 Oct;301(4):F765-72 PMID: 21753077 PMCID: PMC3191800 07/15/2011
  • Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. (Honetschlägerová Z, Sporková A, Kopkan L, Husková Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Kujal P, Vernerová Z, Chábová VC, Tesař V, Cervenka L) J Hypertens 2011 Aug;29(8):1590-601 PMID: 21720266 PMCID: PMC3777565 07/02/2011
  • Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. (Luria A, Bettaieb A, Xi Y, Shieh GJ, Liu HC, Inoue H, Tsai HJ, Imig JD, Haj FG, Hammock BD) Proc Natl Acad Sci U S A 2011 May 31;108(22):9038-43 PMID: 21571638 PMCID: PMC3107315 05/17/2011
  • Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome. (Khan AH, Imig JD) Am J Hypertens 2011 Jul;24(7):816-21 PMID: 21415842 PMCID: PMC3721747 03/19/2011
  • Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. (Sporková A, Kopkan L, Varcabová S, Husková Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Cervenka L) Am J Physiol Regul Integr Comp Physiol 2011 Jun;300(6):R1468-75 PMID: 21411763 PMCID: PMC3119161 03/18/2011
  • Cytochrome P450 eicosanoids and cerebral vascular function. (Imig JD, Simpkins AN, Renic M, Harder DR) Expert Rev Mol Med 2011;13:e7 PMID: 21356152 PMCID: PMC3613250 03/02/2011
  • Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. (Honetschlägerová Z, Z Husková Z, Vaňourková Z, Sporková A, Kramer HJ, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Červenka L, Kopkan L) J Physiol 2011 Jan 1;589(Pt 1):207-19 PMID: 21078594 PMCID: PMC3039270 11/17/2010
  • 20-hydroxyeicosatetraenoic acid and angiotensin: a positive feedback system to cause hypertension. (Imig JD) Hypertension 2010 Nov;56(5):822-3 PMID: 20837886 PMCID: PMC2998348 09/15/2010
  • Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors. (Pavlov TS, Imig JD, Staruschenko A) PPAR Res 2010;2010:703735 PMID: 20613963 PMCID: PMC2896859 07/09/2010
  • Targeting epoxides for organ damage in hypertension. (Imig JD) J Cardiovasc Pharmacol 2010 Oct;56(4):329-35 PMID: 20531214 PMCID: PMC3071608 06/10/2010
  • Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. (Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, Perrow AL, Lepp AN, Kannon MA, Ronnekleiv OK, Alkayed NJ, Falck JR, Tomer KB, Zeldin DC) FASEB J 2010 Oct;24(10):3770-81 PMID: 20495177 PMCID: PMC2996903 05/25/2010
  • Epoxyeicosatrienoic acid analogs and vascular function. (Sudhahar V, Shaw S, Imig JD) Curr Med Chem 2010;17(12):1181-90 PMID: 20158473 PMCID: PMC2855336 02/18/2010
  • Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. (Certíková Chábová V, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerová Z, Vanourková Z, Kopkan L, Kramer HJ, Falck JR, Imig JD, Hammock BD, Vanecková I, Cervenka L) Clin Sci (Lond) 2010 May;118(10):617-32 PMID: 20050826 PMCID: PMC2854172 01/07/2010
  • Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. (Imig JD, Elmarakby A, Nithipatikom K, Wei S, Capdevila JH, Tuniki VR, Sangras B, Anjaiah S, Manthati VL, Sudarshan Reddy D, Falck JR) Front Physiol 2010;1:157 PMID: 21423396 PMCID: PMC3059925 01/01/2010
  • Soluble epoxide hydrolase inhibition modulates vascular remodeling. (Simpkins AN, Rudic RD, Roy S, Tsai HJ, Hammock BD, Imig JD) Am J Physiol Heart Circ Physiol 2010 Mar;298(3):H795-806 PMID: 20035028 PMCID: PMC2838550 12/26/2009
  • Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. (Walkowska A, Skaroupková P, Husková Z, Vanourková Z, Chábová VC, Tesar V, Kramer HJ, Falck JR, Imig JD, Kompanowska-Jezierska E, Sadowski J, Cervenka L) J Hypertens 2010 Mar;28(3):582-93 PMID: 19940786 PMCID: PMC2855337 11/27/2009
  • Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. (Knight SF, Yuan J, Roy S, Imig JD) Am J Physiol Renal Physiol 2010 Jan;298(1):F86-94 PMID: 19906952 PMCID: PMC3774183 11/13/2009
  • Adenosine2A receptors and epoxyeicosatrienoic acids: a recipe for salt and blood pressure regulation. (Imig JD) Hypertension 2009 Dec;54(6):1223-5 PMID: 19822801 PMCID: PMC2783356 10/14/2009
  • Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. (Imig JD, Hammock BD) Nat Rev Drug Discov 2009 Oct;8(10):794-805 PMID: 19794443 PMCID: PMC3021468 10/02/2009
  • Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. (Elmarakby AA, Imig JD) Clin Sci (Lond) 2010 Feb;118(4):291-301 PMID: 19728860 PMCID: PMC2842481 09/05/2009
  • Increased renal proximal convoluted tubule transport contributes to hypertension in Cyp4a14 knockout mice. (Quigley R, Chakravarty S, Zhao X, Imig JD, Capdevila JH) Nephron Physiol 2009;113(4):p23-8 PMID: 19713718 PMCID: PMC2790762 08/29/2009
  • Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. (Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD) Am J Physiol Renal Physiol 2009 Sep;297(3):F740-8 PMID: 19553349 PMCID: PMC2739707 06/26/2009
  • Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. (Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, Hammock BD, Imig JD) Am J Pathol 2009 Jun;174(6):2086-95 PMID: 19435785 PMCID: PMC2684174 05/14/2009
  • Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. (Sudhahar V et al.) Eur J Pharmacol 2009 Apr 1;607(1-3):143-150 PMID: 19374826 04/21/2009
  • Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. (Sudhahar V, Shaw S, Imig JD) Eur J Pharmacol 2009 Apr 1;607(1-3):143-50 PMID: 19326479 PMCID: PMC2664517 03/28/2009
  • Obesity induced renal oxidative stress contributes to renal injury in salt-sensitive hypertension. (Quigley JE, Elmarakby AA, Knight SF, Manhiani MM, Stepp DW, Olearzcyk JJ, Imig JD) Clin Exp Pharmacol Physiol 2009 Jul;36(7):724-8 PMID: 19207724 PMCID: PMC2710419 02/12/2009
  • SPARC ameliorates ovarian cancer-associated inflammation. (Said NA, Elmarakby AA, Imig JD, Fulton DJ, Motamed K) Neoplasia 2008 Oct;10(10):1092-104 PMID: 18813349 PMCID: PMC2546586 09/25/2008
  • Increased blood pressure in mice lacking cytochrome P450 2J5. (Athirakul K, Bradbury JA, Graves JP, DeGraff LM, Ma J, Zhao Y, Couse JF, Quigley R, Harder DR, Zhao X, Imig JD, Pedersen TL, Newman JW, Hammock BD, Conley AJ, Korach KS, Coffman TM, Zeldin DC) FASEB J 2008 Dec;22(12):4096-108 PMID: 18716027 PMCID: PMC2614614 08/22/2008
  • Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. (Chen JK, Chen J, Imig JD, Wei S, Hachey DL, Guthi JS, Falck JR, Capdevila JH, Harris RC) J Biol Chem 2008 Sep 5;283(36):24514-24 PMID: 18606824 PMCID: PMC2528993 07/09/2008
  • Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. (Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, Newman JW, Luria A, Hammock BD, Imig JD) Clin Sci (Lond) 2009 Jan;116(1):61-70 PMID: 18459944 PMCID: PMC2590620 05/08/2008
  • Afferent arteriolar dilation to 11, 12-EET analogs involves PP2A activity and Ca2+-activated K+ Channels. (Imig JD, Dimitropoulou C, Reddy DS, White RE, Falck JR) Microcirculation 2008 Feb;15(2):137-50 PMID: 18260004 PMCID: PMC2654618 02/09/2008
  • Eicosanoids and renal damage in cardiometabolic syndrome. (Imig JD) Expert Opin Drug Metab Toxicol 2008 Feb;4(2):165-74 PMID: 18248310 PMCID: PMC3348552 02/06/2008
  • Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. (Knight SF, Quigley JE, Yuan J, Roy SS, Elmarakby A, Imig JD) Hypertension 2008 Feb;51(2):352-9 PMID: 18158349 PMCID: PMC2491336 12/26/2007
  • TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. (Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM) Am J Physiol Regul Integr Comp Physiol 2008 Jan;294(1):R76-83 PMID: 17989143 PMCID: PMC2820582 11/09/2007
  • Normalization of the ovarian cancer microenvironment by SPARC. (Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K) Mol Cancer Res 2007 Oct;5(10):1015-30 PMID: 17951402 10/24/2007
  • Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. (Elmarakby AA, Quigley JE, Olearczyk JJ, Sridhar A, Cook AK, Inscho EW, Pollock DM, Imig JD) Hypertension 2007 Dec;50(6):1069-76 PMID: 17938380 PMCID: PMC2491337 10/17/2007
  • The roles of intrarenal 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. (Certíková Chábová V, Kramer HJ, Vanecková I, Thumová M, Skaroupková P, Tesar V, Falck JR, Imig JD, Cervenka L) Kidney Blood Press Res 2007;30(5):335-46 PMID: 17785988 09/06/2007
  • Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. (Socha MJ, Manhiani M, Said N, Imig JD, Motamed K) Am J Pathol 2007 Oct;171(4):1104-12 PMID: 17717147 PMCID: PMC1988862 08/25/2007
  • Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. (Guan Y, Zhang Y, Wu J, Qi Z, Yang G, Dou D, Gao Y, Chen L, Zhang X, Davis LS, Wei M, Fan X, Carmosino M, Hao C, Imig JD, Breyer RM, Breyer MD) J Clin Invest 2007 Sep;117(9):2496-505 PMID: 17710229 PMCID: PMC1940235 08/22/2007
  • Obesity, insulin resistance, and renal function. (Knight SF, Imig JD) Microcirculation 2007 Jun-Jul;14(4-5):349-62 PMID: 17613807 07/07/2007
  • Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. (Chábová VC, Kramer HJ, Vanecková I, Vernerová Z, Eis V, Tesar V, Skaroupková P, Thumová M, Schejbalová S, Husková Z, Vanourková Z, Kolský A, Imig JD, Cervenka L) Vascul Pharmacol 2007 Aug-Sep;47(2-3):145-59 PMID: 17604232 07/03/2007
  • Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. (Capdevila JH, Falck JR, Imig JD) Kidney Int 2007 Sep;72(6):683-9 PMID: 17597703 06/29/2007
  • IL6 suppression provides renal protection independent of blood pressure in a murine model of salt-sensitive hypertension. (Manhiani MM, Quigley JE, Socha MJ, Motamed K, Imig JD) Kidney Blood Press Res 2007;30(4):195-202 PMID: 17575466 06/19/2007
  • Novel nitric oxide synthase--dependent mechanism of vasorelaxation in small arteries from hypertensive rats. (Kang KT, Sullivan JC, Sasser JM, Imig JD, Pollock JS) Hypertension 2007 Apr;49(4):893-901 PMID: 17309950 02/21/2007
  • Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. (Dimitropoulou C, West L, Field MB, White RE, Reddy LM, Falck JR, Imig JD) Prostaglandins Other Lipid Mediat 2007 Feb;83(1-2):50-61 PMID: 17259072 01/30/2007
  • Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension. (Elmarakby AA, Williams JM, Imig JD, Pollock JS, Pollock DM) Vascul Pharmacol 2007 Feb;46(2):144-51 PMID: 17112788 PMCID: PMC2746434 11/23/2006
  • Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. (Imig JD) Cardiovasc Drug Rev 2006;24(2):169-88 PMID: 16961727 09/12/2006
  • Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. (Olearczyk JJ, Field MB, Kim IH, Morisseau C, Hammock BD, Imig JD) J Pharmacol Exp Ther 2006 Sep;318(3):1307-14 PMID: 16772540 06/15/2006
  • Eicosanoids and renal vascular function in diseases. (Imig JD) Clin Sci (Lond) 2006 Jul;111(1):21-34 PMID: 16764555 06/13/2006
  • Increased renal vascular reactivity to ANG II after unilateral nephrectomy in the rat involves 20-HETE. (Joly E, Seqqat R, Flamion B, Caron N, Michel A, Imig JD, Kramp R) Am J Physiol Regul Integr Comp Physiol 2006 Oct;291(4):R977-86 PMID: 16675634 05/06/2006
  • Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. (Jin L, Ying Z, Hilgers RH, Yin J, Zhao X, Imig JD, Webb RC) J Pharmacol Exp Ther 2006 Jul;318(1):288-95 PMID: 16569756 03/30/2006
  • PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. (Zhao X, Quigley JE, Yuan J, Wang MH, Zhou Y, Imig JD) Am J Physiol Heart Circ Physiol 2006 Jun;290(6):H2187-95 PMID: 16501022 02/28/2006
  • Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. (Elmarakby AA, Quigley JE, Pollock DM, Imig JD) Hypertension 2006 Mar;47(3):557-62 PMID: 16415373 01/18/2006
  • Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. (Jin L, Foss CE, Zhao X, Mills TM, Wang MH, McCluskey LP, Yaddanapud GS, Falck JR, Imig JD, Webb RC) FASEB J 2006 Mar;20(3):539-41 PMID: 16415108 01/18/2006
  • An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. (Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, Imig JD) J Cardiovasc Pharmacol 2005 Dec;46(6):842-8 PMID: 16306811 PMCID: PMC1444897 11/25/2005
  • Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. (Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW) Am J Physiol Heart Circ Physiol 2006 Mar;290(3):H935-40 PMID: 16284237 11/15/2005
  • Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. (Portik-Dobos V, Harris AK, Song W, Hutchinson J, Johnson MH, Imig JD, Pollock DM, Ergul A) Am J Physiol Regul Integr Comp Physiol 2006 Feb;290(2):R435-41 PMID: 16239374 10/22/2005
  • ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. (Inscho EW, Imig JD, Cook AK, Pollock DM) Br J Pharmacol 2005 Dec;146(7):1019-26 PMID: 16231007 PMCID: PMC1751231 10/19/2005
  • An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. (Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD) Hypertension 2005 Oct;46(4):975-81 PMID: 16157792 PMCID: PMC1444888 09/15/2005
  • Impaired Ca2+ signaling attenuates P2X receptor-mediated vasoconstriction of afferent arterioles in angiotensin II hypertension. (Zhao X, Cook AK, Field M, Edwards B, Zhang S, Zhang Z, Pollock JS, Imig JD, Inscho EW) Hypertension 2005 Sep;46(3):562-8 PMID: 16116048 08/24/2005
  • Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. (Imig JD) Am J Physiol Renal Physiol 2005 Sep;289(3):F496-503 PMID: 16093425 08/12/2005
  • Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. (Williams JM, Zhao X, Wang MH, Imig JD, Pollock DM) Hypertension 2005 Aug;46(2):366-71 PMID: 15967866 06/22/2005
  • Calcium and chloride channel activation by angiotensin II-AT1 receptors in preglomerular vascular smooth muscle cells. (Fuller AJ, Hauschild BC, Gonzalez-Villalobos R, Awayda MS, Imig JD, Inscho EW, Navar LG) Am J Physiol Renal Physiol 2005 Oct;289(4):F760-7 PMID: 15942047 PMCID: PMC1314975 06/09/2005
  • CYP450, COX-2 and Obesity Related Renal Damage. (Imig JD, Zhao X, Dey A, Shaw M) Toxicol Mech Methods 2005;15(2):125-36 PMID: 20021073 01/01/2005
  • L-type calcium channels in the renal microcirculatory response to endothelin. (Pollock DM, Jenkins JM, Cook AK, Imig JD, Inscho EW) Am J Physiol Renal Physiol 2005 Apr;288(4):F771-7 PMID: 15547114 11/18/2004
  • Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. (Zhao X, Dey A, Romanko OP, Stepp DW, Wang MH, Zhou Y, Jin L, Pollock JS, Webb RC, Imig JD) Am J Physiol Regul Integr Comp Physiol 2005 Jan;288(1):R188-96 PMID: 15345471 09/04/2004
  • Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. (Dey A, Williams RS, Pollock DM, Stepp DW, Newman JW, Hammock BD, Imig JD) Obes Res 2004 Aug;12(8):1278-89 PMID: 15340111 09/02/2004
  • P2X receptor-stimulated calcium responses in preglomerular vascular smooth muscle cells involves 20-hydroxyeicosatetraenoic acid. (Zhao X, Falck JR, Gopal VR, Inscho EW, Imig JD) J Pharmacol Exp Ther 2004 Dec;311(3):1211-7 PMID: 15316085 08/19/2004
  • Rofecoxib decreases renal injury in obese Zucker rats. (Dey A, Maric C, Kaesemeyer WH, Zaharis CZ, Stewart J, Pollock JS, Imig JD) Clin Sci (Lond) 2004 Dec;107(6):561-70 PMID: 15307815 08/17/2004
  • Renal autoregulation in P2X1 knockout mice. (Inscho EW, Cook AK, Imig JD, Vial C, Evans RJ) Acta Physiol Scand 2004 Aug;181(4):445-53 PMID: 15283757 07/31/2004
  • 20-HETE or EETs: which arachidonic acid metabolite regulates proximal tubule transporters and contributes to pressure natriuresis? (Imig JD) Am J Physiol Regul Integr Comp Physiol 2004 Jul;287(1):R3-5 PMID: 15191921 06/12/2004
  • Age-related alterations in NOS and oxidative stress in mesenteric arteries from male and female rats. (Sullivan JC, Loomis ED, Collins M, Imig JD, Inscho EW, Pollock JS) J Appl Physiol (1985) 2004 Oct;97(4):1268-74 PMID: 15169747 06/01/2004
  • Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation. (Inscho EW, Cook AK, Murzynowski JB, Imig JD) J Hypertens 2004 Apr;22(4):811-8 PMID: 15126924 05/06/2004
  • Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. (Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD) J Am Soc Nephrol 2004 May;15(5):1244-53 PMID: 15100364 04/22/2004
  • ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses: EDHF Involvement. (Imig JD) Hypertension 2004 Mar;43(3):533-5 PMID: 14757781 02/06/2004
  • Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. (Inscho EW, Cook AK, Imig JD, Vial C, Evans RJ) J Clin Invest 2003 Dec;112(12):1895-905 PMID: 14679185 PMCID: PMC296993 12/18/2003
  • The Bradykinin B2 receptor is required for full expression of renal COX-2 and renin. (Imig JD, Zhao X, Orengo SR, Dipp S, El-Dahr SS) Peptides 2003 Aug;24(8):1141-7 PMID: 14612184 11/13/2003
  • 12-Hydroxyeicosatetraenoic acid participates in angiotensin II afferent arteriolar vasoconstriction by activating L-type calcium channels. (Yiu SS, Zhao X, Inscho EW, Imig JD) J Lipid Res 2003 Dec;44(12):2391-9 PMID: 12951362 09/03/2003
  • Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. (Wang MH, Smith A, Zhou Y, Chang HH, Lin S, Zhao X, Imig JD, Dorrance AM) Hypertension 2003 Oct;42(4):594-9 PMID: 12939236 08/27/2003
  • Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. (Zhao X, Pollock DM, Zeldin DC, Imig JD) Hypertension 2003 Oct;42(4):775-80 PMID: 12900436 08/06/2003
  • Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. (Zhao X, Pollock DM, Inscho EW, Zeldin DC, Imig JD) Hypertension 2003 Mar;41(3 Pt 2):709-14 PMID: 12623984 03/08/2003
  • Kidney CYP450 enzymes: biological actions beyond drug metabolism. (Zhao X, Imig JD) Curr Drug Metab 2003 Feb;4(1):73-84 PMID: 12570747 02/07/2003
  • Contribution of prostaglandin EP(2) receptors to renal microvascular reactivity in mice. (Imig JD, Breyer MD, Breyer RM) Am J Physiol Renal Physiol 2002 Sep;283(3):F415-22 PMID: 12167591 08/09/2002
  • Adaptations of the renal microcirculation to hypertension. (Imig JD, Inscho EW) Microcirculation 2002;9(4):315-28 PMID: 12152107 08/02/2002
  • Renal AT1 receptor protein expression during the early stage of diabetes mellitus. (Harrison-Bernard LM, Imig JD, Carmines PK) Int J Exp Diabetes Res 2002 Apr-Jun;3(2):97-108 PMID: 11991202 PMCID: PMC2478573 05/07/2002
  • Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. (Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD) Hypertension 2002 Feb;39(2 Pt 2):690-4 PMID: 11882632 03/08/2002
  • Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. (Zhuo JL, Imig JD, Hammond TG, Orengo S, Benes E, Navar LG) Hypertension 2002 Jan;39(1):116-21 PMID: 11799089 01/19/2002
  • The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasoconstriction. (Zhao X, Inscho EW, Bondlela M, Falck JR, Imig JD) Am J Physiol Heart Circ Physiol 2001 Nov;281(5):H2089-96 PMID: 11668070 10/23/2001
  • Postglomerular vasoconstriction to angiotensin II and norepinephrine depends on intracellular calcium release. (Imig JD, Cook AK, Inscho EW) Gen Pharmacol 2000 Jun;34(6):409-15 PMID: 11483290 08/03/2001
  • Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. (Imig JD, Falck JR, Wei S, Capdevila JH) J Vasc Res 2001 May-Jun;38(3):247-55 PMID: 11399897 06/16/2001
  • Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. (Imig JD, Zhao X, Falck JR, Wei S, Capdevila JH) J Hypertens 2001 May;19(5):983-92 PMID: 11393683 06/08/2001
  • Unraveling the Mystery of Goldblatt Hypertension. (Navar LG, Zou L, Von Thun A, Tarng Wang C, Imig JD, Mitchell KD) News Physiol Sci 1998 Aug;13():170-176 PMID: 11390784 06/08/2001
  • Calcium signaling pathways utilized by P2X receptors in freshly isolated preglomerular MVSMC. (White SM, Imig JD, Kim TT, Hauschild BC, Inscho EW) Am J Physiol Renal Physiol 2001 Jun;280(6):F1054-61 PMID: 11352845 05/16/2001
  • Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. (Holla VR, Adas F, Imig JD, Zhao X, Price E Jr, Olsen N, Kovacs WJ, Magnuson MA, Keeney DS, Breyer MD, Falck JR, Waterman MR, Capdevila JH) Proc Natl Acad Sci U S A 2001 Apr 24;98(9):5211-6 PMID: 11320253 PMCID: PMC33189 04/26/2001
  • Epoxygenase metabolites. Epithelial and vascular actions. (Imig JD) Mol Biotechnol 2000 Nov;16(3):233-51 PMID: 11252808 03/17/2001
  • Measurement of Renal Tubular Angiotensin II. (Imig JD, Gabriel Navar L) Methods Mol Med 2001;51:427-34 PMID: 21331734 01/01/2001
  • Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. (Zimpelmann J, Kumar D, Levine DZ, Wehbi G, Imig JD, Navar LG, Burns KD) Kidney Int 2000 Dec;58(6):2320-30 PMID: 11115066 12/15/2000
  • Eicosanoid regulation of the renal vasculature. (Imig JD) Am J Physiol Renal Physiol 2000 Dec;279(6):F965-81 PMID: 11097615 11/30/2000
  • Afferent arteriolar reactivity to angiotensin II is enhanced during the early phase of angiotensin II hypertension. (Imig JD) Am J Hypertens 2000 Jul;13(7):810-8 PMID: 10933574 08/10/2000
  • Renal responses to AT1 receptor blockade. (Navar LG, Harrison-Bernard LM, Imig JD, Cervenka L, Mitchell KD) Am J Hypertens 2000 Jan;13(1 Pt 2):45S-54S PMID: 10678288 03/11/2000
  • Nitric oxide-angiotensin II interactions in angiotensin II-dependent hypertension. (Navar LG, Ichihara A, Chin SY, Imig JD) Acta Physiol Scand 2000 Jan;168(1):139-47 PMID: 10691792 02/26/2000
  • Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. (Imig JD, Pham BT, LeBlanc EA, Reddy KM, Falck JR, Inscho EW) Hypertension 2000 Jan;35(1 Pt 2):307-12 PMID: 10642316 01/21/2000
  • Endothelin-mediated calcium signaling in preglomerular smooth muscle cells. (Schroeder AC, Imig JD, LeBlanc EA, Pham BT, Pollock DM, Inscho EW) Hypertension 2000 Jan;35(1 Pt 2):280-6 PMID: 10642311 01/21/2000
  • Cyclooxygenase-2 modulates afferent arteriolar responses to increases in pressure. (Ichihara A, Imig JD, Navar LG) Hypertension 1999 Oct;34(4 Pt 2):843-7 PMID: 10523371 10/16/1999
  • Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. (Imig JD, Falck JR, Inscho EW) Br J Pharmacol 1999 Jul;127(6):1399-405 PMID: 10455289 PMCID: PMC1760652 08/24/1999
  • Early onset salt-sensitive hypertension in bradykinin B(2) receptor null mice. (Cervenka L, Harrison-Bernard LM, Dipp S, Primrose G, Imig JD, El-Dahr SS) Hypertension 1999 Aug;34(2):176-80 PMID: 10454437 08/24/1999
  • Renal endosomes contain angiotensin peptides, converting enzyme, and AT(1A) receptors. (Imig JD, Navar GL, Zou LX, O'Reilly KC, Allen PL, Kaysen JH, Hammond TG, Navar LG) Am J Physiol 1999 Aug;277(2 Pt 2):F303-11 PMID: 10444586 08/13/1999
  • Epoxyeicosatrienoic acids. Biosynthesis, regulation, and actions. (Imig JD) Methods Mol Biol 1999;120:173-92 PMID: 10343317 05/27/1999
  • Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. (Navar LG, Harrison-Bernard LM, Imig JD, Wang CT, Cervenka L, Mitchell KD) J Am Soc Nephrol 1999 Apr;10 Suppl 12:S266-72 PMID: 10201881 04/14/1999
  • ATP-mediated Ca2+ signaling in preglomerular smooth muscle cells. (Inscho EW, Schroeder AC, Deichmann PC, Imig JD) Am J Physiol 1999 Mar;276(3 Pt 2):F450-6 PMID: 10070169 03/10/1999
  • Afferent arteriolar vasodilation to the sulfonimide analog of 11, 12-epoxyeicosatrienoic acid involves protein kinase A. (Imig JD, Inscho EW, Deichmann PC, Reddy KM, Falck JR) Hypertension 1999 Jan;33(1 Pt 2):408-13 PMID: 9931138 02/04/1999
  • Neuronal nitric oxide synthase-dependent afferent arteriolar function in angiotensin II-induced hypertension. (Ichihara A, Imig JD, Navar LG) Hypertension 1999 Jan;33(1 Pt 2):462-6 PMID: 9931148 02/04/1999
  • Purinoceptor-mediated calcium signaling in preglomerular smooth muscle cells. (Inscho EW, LeBlanc EA, Pham BT, White SM, Imig JD) Hypertension 1999 Jan;33(1 Pt 2):195-200 PMID: 9931104 02/04/1999
  • Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats. (Inscho EW, Imig JD, Deichmann PC, Cook AK) J Am Soc Nephrol 1999 Jan;10 Suppl 11:S178-83 PMID: 9892160 01/19/1999
  • Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: interaction with neuronal NOS. (Ichihara A, Imig JD, Inscho EW, Navar LG) Am J Physiol 1998 Oct;275(4 Pt 2):F605-12 PMID: 9755132 10/01/1998
  • Heterogeneous activation mechanisms in the renal microvasculature. (Navar LG, Inscho EW, Imig JD, Mitchell KD) Kidney Int Suppl 1998 Sep;67:S17-21 PMID: 9736247 09/15/1998
  • Renal uptake of circulating angiotensin II in Val5-angiotensin II infused rats is mediated by AT1 receptor. (Zou LX, Imig JD, Hymel A, Navar LG) Am J Hypertens 1998 May;11(5):570-8 PMID: 9633793 06/20/1998
  • Interactive nitric oxide-angiotensin II influences on renal microcirculation in angiotensin II-induced hypertension. (Ichihara A, Imig JD, Inscho EW, Navar LG) Hypertension 1998 Jun;31(6):1255-60 PMID: 9622138 06/11/1998
  • Neuronal nitric oxide synthase modulates rat renal microvascular function. (Ichihara A, Inscho EW, Imig JD, Navar LG) Am J Physiol 1998 Mar;274(3 Pt 2):F516-24 PMID: 9530268 04/08/1998
  • Calcium mobilization contributes to pressure-mediated afferent arteriolar vasoconstriction. (Inscho EW, Cook AK, Mui V, Imig JD) Hypertension 1998 Jan;31(1 Pt 2):421-8 PMID: 9453339 02/07/1998
  • Intrarenal production of angiotensin II. (Navar LG, Imig JD, Zou L, Wang CT) Semin Nephrol 1997 Sep;17(5):412-22 PMID: 9316209 10/08/1997
  • Afferent arteriolar responses to ANG II involve activation of PLA2 and modulation by lipoxygenase and P-450 pathways. (Imig JD, Deichmann PC) Am J Physiol 1997 Aug;273(2 Pt 2):F274-82 PMID: 9277588 08/01/1997
  • Agonist-induced calcium regulation in freshly isolated renal microvascular smooth muscle cells. (Inscho EW, Mason MJ, Schroeder AC, Deichmann PC, Stiegler KD, Imig JD) J Am Soc Nephrol 1997 Apr;8(4):569-79 PMID: 10495786 04/01/1997
  • Effects of phospholipase A2, 12-lipoxygenase, and cyclooxygenase inhibitors in the feline pulmonary bed. (Kaye AD, Nossaman BD, Smith DE, Ibrahim IN, Imig JD, Kadowitz PJ) Am J Physiol 1997 Apr;272(4 Pt 1):L573-9 PMID: 9142927 04/01/1997
  • Role of renal nerves in afferent arteriolar reactivity in angiotensin-induced hypertension. (Ichihara A, Inscho EW, Imig JD, Michel RE, Navar LG) Hypertension 1997 Jan;29(1 Pt 2):442-9 PMID: 9039140 01/01/1997
  • Afferent and efferent arteriolar vasoconstriction to angiotensin II and norepinephrine involves release of Ca2+ from intracellular stores. (Inscho EW, Imig JD, Cook AK) Hypertension 1997 Jan;29(1 Pt 2):222-7 PMID: 9039106 01/01/1997
  • Actions of epoxygenase metabolites on the preglomerular vasculature. (Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR) J Am Soc Nephrol 1996 Nov;7(11):2364-70 PMID: 8959626 11/01/1996
  • Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats. (Zou LX, Imig JD, von Thun AM, Hymel A, Ono H, Navar LG) Hypertension 1996 Oct;28(4):669-77 PMID: 8843896 10/01/1996
  • Identification of a putative microvascular oxygen sensor. (Harder DR, Narayanan J, Birks EK, Liard JF, Imig JD, Lombard JH, Lange AR, Roman RJ) Circ Res 1996 Jul;79(1):54-61 PMID: 8925569 07/01/1996
  • Afferent arteriolar response to arachidonic acid: involvement of metabolic pathways. (Imig JD, Navar LG) Am J Physiol 1996 Jul;271(1 Pt 2):F87-93 PMID: 8760247 07/01/1996
  • Paracrine regulation of the renal microcirculation. (Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD) Physiol Rev 1996 Apr;76(2):425-536 PMID: 8618962 04/01/1996
  • Renal accumulation of circulating angiotensin II in angiotensin II-infused rats. (Zou LX, Hymel A, Imig JD, Navar LG) Hypertension 1996 Mar;27(3 Pt 2):658-62 PMID: 8613220 03/01/1996
  • Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. (Imig JD, Zou AP, Stec DE, Harder DR, Falck JR, Roman RJ) Am J Physiol 1996 Jan;270(1 Pt 2):R217-27 PMID: 8769805 01/01/1996
  • Effect of P-450 omega-hydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. (Zou AP, Imig JD, Ortiz de Montellano PR, Sui Z, Falck JR, Roman RJ) Am J Physiol 1994 Jun;266(6 Pt 2):F934-41 PMID: 8023972 06/01/1994
  • Cytochrome P-450 inhibitors alter afferent arteriolar responses to elevations in pressure. (Imig JD, Zou AP, Ortiz de Montellano PR, Sui Z, Roman RJ) Am J Physiol 1994 May;266(5 Pt 2):H1879-85 PMID: 8203587 05/01/1994
  • Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. (Zou AP, Imig JD, Kaldunski M, Ortiz de Montellano PR, Sui Z, Roman RJ) Am J Physiol 1994 Feb;266(2 Pt 2):F275-82 PMID: 8141328 02/01/1994
  • Elevated renovascular tone in young spontaneously hypertensive rats. Role of cytochrome P-450. (Imig JD, Falck JR, Gebremedhin D, Harder DR, Roman RJ) Hypertension 1993 Sep;22(3):357-64 PMID: 8349328 09/01/1993
  • Chloride alters renal blood flow autoregulation in deoxycorticosterone-treated rats. (Imig JD, Passmore JC, Anderson GL, Jimenez AE) J Lab Clin Med 1993 Apr;121(4):608-13 PMID: 8454943 04/01/1993
  • Role of cytochrome P-450 in elevating renal vascular tone in spontaneously hypertensive rats. (Gebremedhin D, Ma YH, Imig JD, Harder DR, Roman RJ) J Vasc Res 1993 Jan-Feb;30(1):53-60 PMID: 8435472 01/01/1993
  • Modulation of vascular tone in renal microcirculation by erythrocytes: role of EDRF. (Imig JD, Gebremedhin D, Harder DR, Roman RJ) Am J Physiol 1993 Jan;264(1 Pt 2):H190-5 PMID: 8430846 01/01/1993
  • Nitric oxide modulates vascular tone in preglomerular arterioles. (Imig JD, Roman RJ) Hypertension 1992 Jun;19(6 Pt 2):770-4 PMID: 1592479 06/01/1992
  • Small artery resistance increases during the development of renal hypertension. (Imig JD, Anderson GL) Hypertension 1991 Mar;17(3):317-22 PMID: 1999362 03/01/1991
  • Last update: 08/31/2015